BrainStorm Cell Therapeutics Secures $1 Million Strategic Financing Deal with Institutional Partners

BrainStorm Cell Therapeutics Secures $1 Million Strategic Financing

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a prominent player in the development of adult stem cell therapies, has recently disclosed a significant strategic financing initiative. The firm has entered into a definitive agreement for a $1 million private placement aimed at bolstering its operational momentum and supporting advancements in neurodegenerative diseases treatments, particularly with its innovative NurOwn® platform.

Key Points of the Financing Agreement

The financial arrangement is structured to reflect BrainStorm's ongoing operational progress, with the common stock priced at $0.60 per share. This price indicates a notable premium compared to its recent market close of $0.54 on February 9, 2026, thus highlighting strong institutional support and confidence in BrainStorm's trajectory.

An integral aspect of the financing is the warrant structure, which offers investors 120% warrant coverage for a five-year term at an exercise price of $1.00 per share. This price point signifies a robust long-term valuation target and illustrates the confidence institutional partners have in the company's future growth. The funding will be executed in two tranches; the first half of $500,000 has already been received, while the second half is expected within the next 30 days.

Additionally, BrainStorm is required to file a registration statement for the resale of the common stock and warrants within 45 days, providing a clear path for investors to realize returns on their investment.

Context and Future Plans

This financing comes on the heels of a crucial period for BrainStorm Cell Therapeutics, as the company finalizes its Phase 3b trial design under a Special Protocol Assessment (SPA) and engages in discussions regarding a pending Citizens Petition for Accelerated Approval with regulatory authorities. Chaim Lebovits, President and CEO, emphasized that obtaining this financing at a premium serves as a testament to the anticipated success of the NurOwn treatment for ALS, showcasing the strong belief from partners in Brainstorm's mission.

Lebovits remarked, “The $1.00 warrant strike price, specifically, indicates where we envision our company heading as we prepare for our Phase 3b trial and continue our focused engagement with regulatory authorities.”

The proceeds from this funding will aid in various initiatives, primarily supporting regulatory activities, prepayments for the upcoming Phase 3b trial of NurOwn® targeting ALS, as well as general operational purposes.

About NurOwn® and BrainStorm Cell Therapeutics

The NurOwn® technology represents a compelling therapeutic approach that utilizes autologous mesenchymal stem cells (MSCs) to create neurotrophic factor-secreting cells (MSC-NTF cells). This innovative technology aims to deliver therapeutic signals essential in managing neuroinflammation and promoting neuroprotection for patients suffering from ALS and other neurodegenerative disorders.

The clinical efforts surrounding NurOwn® have garnered significant attention; it has secured Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Past trials have provided critical insights into ALS, revealing vital pharmacogenomic responses and identifying biomarkers that are essential in tracking disease progression.

BrainStorm is also advancing additional research in other neurodegenerative diseases such as progressive multiple sclerosis, with encouraging results from Phase 2 trials. Furthermore, the firm is developing an allogeneic exosome-based platform aimed at delivering therapeutic proteins and nucleic acids, signaling a broad commitment to innovation in regenerative medicine.

Conclusion

In summary, the strategic financing not only affirms BrainStorm's market position but also highlights institutional confidence in the potential of NurOwn® as a potential breakthrough treatment for ALS. As the company prepares for its upcoming trials and regulatory discussions, it seeks to make significant strides in improving treatments for those affected by neurodegenerative diseases. This venture represents a crucial step in forging a path toward effective therapies, aligning investor interests with patient needs, and exemplifying BrainStorm's dedication to advancing healthcare solutions.

For more information about BrainStorm Cell Therapeutics and its initiatives, visit www.brainstorm-cell.com.